BioWorld Science https://www.bioworld.com/rss en-us Bundibugyo is harsh reminder of need for broad vaccine strategies http://www.bioworld.com/articles/731356 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731356-bundibugyo-is-harsh-reminder-of-need-for-broad-vaccine-strategies Virus and vaccine illustration New PROTACs reported in Prelude Therapeutics patent http://www.bioworld.com/articles/731172 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731172-new-protacs-reported-in-prelude-therapeutics-patent Kimia Therapeutics patents new DHX9 inhibitors http://www.bioworld.com/articles/731171 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731171-kimia-therapeutics-patents-new-dhx9-inhibitors Convalife Pharmaceuticals discovers new CFB inhibitors http://www.bioworld.com/articles/731170 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731170-convalife-pharmaceuticals-discovers-new-cfb-inhibitors Shanghai Meiyue Biotech discloses new EHMT2 inhibitors N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors potentially useful for the treatment of cancer, autoimmune disease, metabolic diseases, gastrointestinal and inflammatory disorders.]]> http://www.bioworld.com/articles/731169 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731169-shanghai-meiyue-biotech-discloses-new-ehmt2-inhibitors Iksuda and UCL report new B7-H3-targeting ADCs http://www.bioworld.com/articles/731168 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731168-iksuda-and-ucl-report-new-b7-h3-targeting-adcs Dual-payload ADC holds promise for treating HER2+ tumors http://www.bioworld.com/articles/731163 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731163-dual-payload-adc-holds-promise-for-treating-her2-tumors Antibody-drug conjugates floating on light purple background Triazine-based dual HDAC/PI3K inhibitors with potential for TNBC therapy reported http://www.bioworld.com/articles/731162 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731162-triazine-based-dual-hdac-pi3k-inhibitors-with-potential-for-tnbc-therapy-reported Illustration of triple-negative breast cancer cells TOP2B upregulation drives anthracycline-induced cardiotoxicity, can be prevented by ASO treatment http://www.bioworld.com/articles/731161 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731161-top2b-upregulation-drives-anthracycline-induced-cardiotoxicity-can-be-prevented-by-aso-treatment IV drips Biocryst’s BCX-17725 as new approach for Netherton syndrome http://www.bioworld.com/articles/731160 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731160-biocrysts-bcx-17725-as-new-approach-for-netherton-syndrome Skin anatomy and DNA China’s NMPA clears KAT6 inhibitor SYH-2095 for clinic http://www.bioworld.com/articles/731159 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731159-chinas-nmpa-clears-kat6-inhibitor-syh-2095-for-clinic Wooden stamp with China flag Korro Bio nominates new candidate for AATD SERPINA1.]]> http://www.bioworld.com/articles/731158 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731158-korro-bio-nominates-new-candidate-for-aatd Liver and lungs Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis http://www.bioworld.com/articles/731157 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731157-recludixs-first-in-class-stat6-inhibitor-shows-efficacy-in-atopic-dermatitis SOS1 inhibitors disclosed in Mirati Therapeutics patent http://www.bioworld.com/articles/731153 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731153-sos1-inhibitors-disclosed-in-mirati-therapeutics-patent Nxera Pharma prepares and tests new GPR17 antagonists http://www.bioworld.com/articles/731152 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731152-nxera-pharma-prepares-and-tests-new-gpr17-antagonists Shouyao Holdings divulges new RET inhibitors http://www.bioworld.com/articles/731151 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731151-shouyao-holdings-divulges-new-ret-inhibitors Dgenthera, University of North Carolina report new radiolabeled bioactive compounds http://www.bioworld.com/articles/731150 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731150-dgenthera-university-of-north-carolina-report-new-radiolabeled-bioactive-compounds Neurolambda Therapeutics patents new TYK2 inhibitors http://www.bioworld.com/articles/731149 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731149-neurolambda-therapeutics-patents-new-tyk2-inhibitors KC-1101 has best-in-class potential for TACC3-expressing tumors http://www.bioworld.com/articles/731144 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731144-kc-1101-has-best-in-class-potential-for-tacc3-expressing-tumors Cancer cell, dropper, test tubes Aigen’s AIG-07025 shows potential for BRCA/HRD-driven cancers BRCA gene mutations or homologous recombination deficiency (HRD). Targeting USP1 has emerged as a promising approach to overcome resistance observed in BRCA/HRD-driven tumors. Aigen Sciences Inc. developed and presented data for AIG-07025, a potent and selective USP1 inhibitor.]]> http://www.bioworld.com/articles/731143 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731143-aigens-aig-07025-shows-potential-for-brca-hrd-driven-cancers Microscope with slide IND-enabling studies of adult RPE stem cell product for dry AMD http://www.bioworld.com/articles/731142 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731142-ind-enabling-studies-of-adult-rpe-stem-cell-product-for-dry-amd Senior eye exam MD Anderson gains IND nod for CD94-targeted CAR T therapy http://www.bioworld.com/articles/731141 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731141-md-anderson-gains-ind-nod-for-cd94-targeted-car-t-therapy Computer visualization of a CAR T cell attacking a cancer cell. Computer visualization of a CAR T cell attacking a cancer cell. Credit: C. Bock, CeMM. GPX-002 restores β-cell function in a diabetes model http://www.bioworld.com/articles/731140 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731140-gpx-002-restores-cell-function-in-a-diabetes-model Pancreas anatomy illustration Harbour Biomed’s LET-003 shows promise for obesity http://www.bioworld.com/articles/731139 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731139-harbour-biomeds-let-003-shows-promise-for-obesity Illustration of monoclonal antibody hovering between doctor's hands AAV-encoded dimeric PICK1 inhibitors reduce inflammatory, neuropathic pain in mice http://www.bioworld.com/articles/731138 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731138-aav-encoded-dimeric-pick1-inhibitors-reduce-inflammatory-neuropathic-pain-in-mice WHO declares Ebola outbreak a public health emergency of international concern http://www.bioworld.com/articles/731355 Mon, 18 May 2026 00:00:00 -0400 https://www.bioworld.com/articles/731355-who-declares-ebola-outbreak-a-public-health-emergency-of-international-concern Microscopic view of the ebola virus New KRAS mutant inhibitors reported in Université de Montréal patent http://www.bioworld.com/articles/731135 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731135-new-kras-mutant-inhibitors-reported-in-universite-de-montreal-patent Hangzhou Institute of Medicine discovers new CDK2/cyclin E1 inhibitors http://www.bioworld.com/articles/731134 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731134-hangzhou-institute-of-medicine-discovers-new-cdk2-cyclin-e1-inhibitors Antelope Therapeutics patents new antibody-drug conjugates for cancer http://www.bioworld.com/articles/731133 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731133-antelope-therapeutics-patents-new-antibody-drug-conjugates-for-cancer CSPC Megalith Biopharmaceutical discloses new CDCP1-targeting ADCs http://www.bioworld.com/articles/731132 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731132-cspc-megalith-biopharmaceutical-discloses-new-cdcp1-targeting-adcs